rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GTCB 2007 ******

2.783 Posts
Pagina: «« 1 ... 83 84 85 86 87 ... 140 »» | Laatste | Omlaag ↓
  14. [verwijderd] 18 mei 2007 20:40

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0






    alubli () @5/18/2007 8:34:49 PM Blokkeer
    Je neemt me de woorden uit de mond die ik NOG (!) niet heb gezegd m.b.t. die Cor, Pret.......:(
    BIO Dree

    Op Mvis gepost....
    BIO Dree
  18. [verwijderd] 18 mei 2007 20:52

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Posted by: DewDiligence
    In reply to: None Date:5/17/2007 12:37:34 PM
    Post #of 3574

    Down on the Biopharm

    [This is a new and bullish article on transgenic drug production from the UK’s BioPharma Reporter.]

    http://www.biopharma-reporter.com/news/printNewsBis.asp?id=76607

    >>
    By Anna Lewcock
    17-May-2007

    The critical role transgenic animals could play in the future of biopharmaceutical production has been tackled by a task force in a new report out this week.

    The potential such animals could have in the manufacture of biopharmaceutical proteins has been one of the major incentives driving investigation and creation of transgenic animals, and with therapeutic products derived from these genetically modified creatures now beginning to gain regulatory approval, commercial interest is in the technique is heating up.

    The significant cost savings to be had through using transgenic livestock instead of traditional methods of protein production have been well documented, and comparisons make for stark reading.

    To illustrate, experts have estimated that producing a single gram of therapeutic protein using traditional cell lines such as Chinese Hamster Ovary (CHO) cells can cost anywhere from $300 to $3,000 (€221 to €2210). In contrast, using a transgenic goat to produce the protein in milk drops the cost to $20-$105 per gram, and transgenic hen eggs are even cheaper, working out at around $0.1-$0.25 per gram of protein.

    The initial capital expenditure is also somewhat less intensive using transgenic livestock, with the cost of constructing a new facility based on traditional cell-based techniques hitting $150m - $400m, compared with the cost of a transgenic goat or cow at $10,000 - $50,000, or a transgenic chicken coming in at $1,000.

    "With moderate alterations in production practices, it is possible to take advantage of the tremendous protein-producing capabilities of domestic livestock," states the report, published this week by the Council for Agricultural Science and Technology (CAST).

    "Biopharming, the production of biopharmaceuticals using domestic livestock, can have significant advantages compared with other production methods in terms of safety, biological activity, and production costs."

    Back in June 2006 the European Medicines Agency (EMEA) gave the very first European approval of a transgenically produced protein product. ATryn, produced by US firm GTC Biotherapeutics, is produced in the milk of goats that have a transgene for human antithrombin, and is used as an anticoagulant to treat a rare congenital disease.

    This first step to move transgenically produced protein products out onto the market could prove to be the just the tip of the iceberg, with all eyes on ATryn to see how it fares out in the cold reality of the marketplace.

    According to the chairperson of the CAST task force, Carol Keefer, wide-scale commercial adoption of protein production using transgenic animals is getting closer and closer, with GTC's product cutting a path for other biotech companies.

    "I think as soon as ATryn goes to market and proves acceptable and profitable, more pharma companies will explore the use of transgenic animals for protein production," she told in-PharmaTechnologist.com.

    Already there are many companies investing in research into producing bioproducts through transgenic livestock. The majority are still in research stages, but US company Avigenics and Netherlands-based firm Pharming currently both have products in clinical trials.

    Aside from the economic cost benefits biopharming appears to promise, the procedure can also offer other distinct advantages over current cell-based production methods.

    For example, using transgenic animals to produce biopharmaceuticals currently harvested from human tissues represents a safer technique in terms of preventing transmission of human diseases such as HIV/AIDS or Creuzfeldt-Jakob disease, say the report authors.

    In some cases, using transgenic animals can also lead to production of a better protein, said Keefer, i.e. a protein more similar to the version naturally produced in humans. "Proteins are modified during production in the cell, and transgenic animals can do these modifications in a manner more similar to the human-produced protein than other production systems such as yeast or bacteria."

    Despite the apparent attractions of biopharming, the report acknowledges that it is critical to establish economic feasibility of the process before it will be adopted by drug firms. For example, issues surrounding protein purification can seriously affect the ultimate economics and commercialisation of a final product.

    Feasibility concerns or lack of funding have caused some commercial pharma projects applying these new technologies to be scrapped or delayed on a purely economic basis.

    "These are business issues caused not necessarily by technical challenges but by unknown factors that arise as new technologies develop without an established track record or sufficient guidelines for completing the necessary regulatory steps," states the report.

    "In fact, regulatory guidelines are being developed concurrently with the establishment of the new technology, creating uncertainty within the business community as to the costs and timelines associated with recombinant protein production."

    While transgenic livestock are likely to play an increasingly significant role in the production of therapeutic proteins, Keefer was by no means suggesting that it would to do away with other production methods altogether.

    "Each production method has its advantages and disadvantages," she said. "Depending on the protein, the amount of protein needed (based on market demand and dosage required), and the activity of the protein, a company would choos
  19. [verwijderd] 18 mei 2007 20:53

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    "Each production method has its advantages and disadvantages," she said. "Depending on the protein, the amount of protein needed (based on market demand and dosage required), and the activity of the protein, a company would choose the best suited system. [For example] if the therapeutic protein could have an effect on the physiology of the transgenic animal, then you would either modify the protein so it was inactive during production, or perhaps choose another system."

    Despite this, the authors of the report clearly have very high expectations of biopharming and the part it will play in the production of new medications to treat human diseases. The unique possibilities that transgenic livestock present in this area are too big a prospect to be ignored, and the authors call for "continued support of research by both government and commercial entities...such that additional promising biotherapies can be developed."

    BIO Dree
  20. [verwijderd] 18 mei 2007 20:57

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Pff Dree kom je nu mee.........Tico roept het al jaar(en)


    kijk je hebt
    1:TA
    2;FUnda
    3:Traders


    Afhankelijk van de omstandigeheden moet je kiezen tussen die 3 strategien....welke nemen we vandaag :)))

    Bij Ph is de keus duidelijk sinds dec 2006, maar had je al ee 1/2 jaar aan kunnen zien komen
2.783 Posts
Pagina: «« 1 ... 83 84 85 86 87 ... 140 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.070
AB InBev 2 5.518
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.730
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.750
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 191
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.753
Aedifica 3 916
Aegon 3.258 322.870
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.894
Agfa-Gevaert 14 2.051
Ahold 3.538 74.340
Air France - KLM 1.025 35.057
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.042
Alfen 16 24.912
Allfunds Group 4 1.475
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.340
AMG 971 133.669
AMS 3 73
Amsterdam Commodities 305 6.697
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.014
Apollo Alternative Assets 1 17
Apple 5 383
Arcadis 252 8.784
Arcelor Mittal 2.034 320.745
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.326
Aroundtown SA 1 219
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.240
ASML 1.766 107.949
ASR Nederland 21 4.500
ATAI Life Sciences 1 7
Atenor Group 1 498
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.682
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.403